Home › ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...
 

Keywords :   


ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...

2014-06-02 10:20:00| Logistics - Topix.net

SAR3419 is a CD19-targeting ADC developed by ImmunoGen and licensed to Sanofi as part of a broader collaboration between the companies.

Tags: data phase clinical favorable

Category:Transportation and Logistics

Latest from this category

All news
16.11Tropical Storm Sara Graphics
16.11Tropical Storm Sara Forecast Discussion Number 11
16.11Tropical Storm Sara Wind Speed Probabilities Number 11
16.11Summary for Tropical Storm Sara (AT4/AL192024)
16.11Tropical Storm Sara Public Advisory Number 11
16.11Tropical Storm Sara Forecast Advisory Number 11
16.11Atlantic Tropical Weather Outlook
16.11Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
16.11HestraFallLine3
16.11GBA
16.11 SKY PAD 3.0 XL
16.1125th
16.112022taxDVD
16.11
16.11
16.11 e
More »